keyword
MENU ▼
Read by QxMD icon Read
search

Prodromal AD

keyword
https://www.readbyqxmd.com/read/29325011/cognitive-complaints-in-memory-clinic-patients-and-in-depressive-patients-an-interpretative-phenomenological-analysis
#1
Lisa Miebach, Steffen Wolfsgruber, Ingo Frommann, Klaus Fließbach, Frank Jessen, Rachel Buckley, Michael Wagner
Background and Objectives: Cognitive complaints are discussed as early signs of Alzheimer's disease (AD). However, they are also very common in cognitively normal older adults and in patients with depression. Qualitative, interview-based approaches might be useful to identify those features of cognitive complaints specific for the experiences of cognitive decline in preclinical or prodromal AD versus those complaints typically reported by depressed patients. Research Design and Methods: A semi-structured interview was administered to 21 cognitively normal older adults (HC), 18 nondemented memory clinic patients (MC), and 11 patients with a major depression (MD), all above 55 years...
January 8, 2018: Gerontologist
https://www.readbyqxmd.com/read/29321235/comparing-18f-av-1451-with-csf-t-tau-and-p-tau-for-diagnosis-of-alzheimer-disease
#2
Niklas Mattsson, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Michael Schöll, Philip S Insel, Douglas Hägerström, Tomas Ohlsson, Henrik Zetterberg, Kaj Blennow, Jonas Jögi, Oskar Hansson
OBJECTIVE: To compare PET imaging of tau pathology with CSF measurements (total tau [t-tau] and phosphorylated tau [p-tau]) in terms of diagnostic performance for Alzheimer disease (AD). METHODS: We compared t-tau and p-tau and 18F-AV-1451 in 30 controls, 14 patients with prodromal AD, and 39 patients with Alzheimer dementia, recruited from the Swedish BioFINDER study. All patients with AD (prodromal and dementia) were screened for amyloid positivity using CSF β-amyloid 42...
January 10, 2018: Neurology
https://www.readbyqxmd.com/read/29321140/cerebrospinal-fluid-alzheimer-biomarkers-can-be-useful-for-discriminating-dementia-with-lewy-bodies-from-alzheimer-s-disease-at-the-prodromal-stage
#3
Olivier Bousiges, Stephanie Bombois, Susanna Schraen, David Wallon, Muriel Muraine Quillard, Audrey Gabelle, Sylvain Lehmann, Claire Paquet, Elodie Amar-Bouaziz, Eloi Magnin, Carole Miguet-Alfonsi, Xavier Delbeuck, Thomas Lavaux, Pierre Anthony, Nathalie Philippi, Frederic Blanc
BACKGROUND: Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181, total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage. METHODS: A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively...
January 10, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29316528/altered-structural-network-organization-in-cognitively-normal-individuals-with-amyloid-pathology
#4
Olga Voevodskaya, Joana B Pereira, Giovanni Volpe, Olof Lindberg, Erik Stomrud, Danielle van Westen, Eric Westman, Oskar Hansson
Recent findings show that structural network topology is disrupted in Alzheimer's disease (AD), with changes occurring already at the prodromal disease stages. Amyloid accumulation, a hallmark of AD, begins several decades before symptom onset, and its effects on brain connectivity at the earliest disease stages are not fully known. We studied global and local network changes in a large cohort of cognitively healthy individuals (N = 299, Swedish BioFINDER study) with and without amyloid-β (Aβ) pathology (based on cerebrospinal fluid Aβ42/Aβ40 levels)...
December 7, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/29277405/transcranial-magnetic-stimulation-of-the-precuneus-enhances-memory-and-neural-activity-in-prodromal-alzheimer-s-disease
#5
Giacomo Koch, Sonia Bonnì, Maria Concetta Pellicciari, Elias P Casula, Matteo Mancini, Romina Esposito, Viviana Ponzo, Silvia Picazio, Francesco Di Lorenzo, Laura Serra, Caterina Motta, Michele Maiella, Camillo Marra, Mara Cercignani, Alessandro Martorana, Carlo Caltagirone, Marco Bozzali
Memory loss is one of the first symptoms of typical Alzheimer's disease (AD), for which there are no effective therapies available. The precuneus (PC) has been recently emphasized as a key area for the memory impairment observed in early AD, likely due to disconnection mechanisms within large-scale networks such as the default mode network (DMN). Using a multimodal approach we investigated in a two-week, randomized, sham-controlled, double-blinded trial the effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) of the PC on cognition, as measured by the Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite in 14 patients with early AD (7 females)...
December 19, 2017: NeuroImage
https://www.readbyqxmd.com/read/29248892/peripheral-inflammation-in-prodromal-alzheimer-s-and-lewy-body-dementias
#6
Eleanor King, John Tiernan O'Brien, Paul Donaghy, Christopher Morris, Nicola Barnett, Kirsty Olsen, Carmen Martin-Ruiz, John-Paul Taylor, Alan J Thomas
OBJECTIVES: There is growing evidence for the role of systemic inflammation in Alzheimer's disease (AD) and other neurodegenerative diseases; however the systemic inflammatory profile in dementia with Lewy bodies (DLB) has never before been investigated. This study aimed to characterise systemic inflammatory mediators in established DLB and AD, as well as in their prodromal, mild cognitive impairment (MCI) phases. METHODS: We obtained plasma samples from patients with DLB (n=37), AD (n=20), MCI with DLB profile (n=38), MCI with AD profile (n=20) and healthy control subjects (n=20)...
December 16, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29242123/ensemble-of-random-forests-one-vs-rest-classifiers-for-mci-and-ad-prediction-using-anova-cortical-and-subcortical-feature-selection-and-partial-least-squares
#7
J Ramírez, J M Górriz, A Ortiz, F J Martínez-Murcia, F Segovia, D Salas-Gonzalez, D Castillo-Barnes, I A Illán, C G Puntonet
BACKGROUND: Alzheimer's disease (AD) is the most common cause of dementia in the elderly and affects approximately 30 million individuals worldwide. Mild cognitive impairment (MCI) is very frequently a prodromal phase of AD, and existing studies have suggested that people with MCI tend to progress to AD at a rate of about 10% to 15% per year. However, the ability of clinicians and machine learning systems to predict AD based on MRI biomarkers at an early stage is still a challenging problem that can have a great impact in improving treatments...
December 11, 2017: Journal of Neuroscience Methods
https://www.readbyqxmd.com/read/29237798/differential-effects-of-cognitive-reserve-and-brain-reserve-on-cognition-in-alzheimer-disease
#8
Colin Groot, Anna C van Loenhoud, Frederik Barkhof, Bart N M van Berckel, Teddy Koene, Charlotte C Teunissen, Philip Scheltens, Wiesje M van der Flier, Rik Ossenkoppele
OBJECTIVE: To examine cross-sectional effects of cognitive reserve (CR) and brain reserve (BR) on cognition across the spectrum of Alzheimer disease (AD). METHODS: We included 663 AD biomarker-positive participants with dementia (probable AD, n = 462) or in the predementia stages (preclinical/prodromal AD, n = 201). Education was used as a proxy of CR and intracranial volume as a proxy of BR. Cognition was assessed across 5 domains (memory, attention, language, visuospatial, and executive functions)...
December 13, 2017: Neurology
https://www.readbyqxmd.com/read/29231140/up-regulation-of-dmn-connectivity-in-mild-cognitive-impairment-via-network-based-cognitive-training
#9
Matteo De Marco, Francesca Meneghello, Cristina Pilosio, Jessica Rigon, Annalena Venneri
BACKGROUND: Previous work designed a network-based protocol of cognitive training. This programme exploits a mechanism of induced task-oriented co-activation of multiple regions that are part of the default mode network (DMN), to induce functional rewiring and increased functional connectivity within this network. OBJECTIVE: In this study, the programme was administered to patients with a diagnosis of mild cognitive impairment to test its effects in a clinical sample...
December 11, 2017: Current Alzheimer Research
https://www.readbyqxmd.com/read/29224729/different-cognitive-complaint-profiles-in-memory-clinic-and-depressive-patients
#10
Lisa Miebach, Steffen Wolfsgruber, Ingo Frommann, Rachel Buckley, Michael Wagner
OBJECTIVE: Cognitive complaints are considered early indicators of incipient Alzheimer's disease (AD) but are very common in geriatric patients, especially in patients with major depressive disorder (MDD). The clinical assessment of cognitive complaints is still poorly operationalized. Recent qualitative research suggests that certain phenomenologic complaint themes may have some specificity for prodromal AD. The aim of the study was to replicate and explore their occurrence in a clinical setting...
November 8, 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/29221491/a-phase-iii-randomized-trial-of-gantenerumab-in-prodromal-alzheimer-s-disease
#11
Susanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura
BACKGROUND: Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer's disease (AD). METHODS: In this randomized, double-blind, placebo-controlled phase III study, we investigated gantenerumab over 2 years. Patients were randomized to gantenerumab 105 mg or 225 mg or placebo every 4 weeks by subcutaneous injection...
December 8, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/29220126/can-the-retina-be-used-to-diagnose-and-plot-the-progression-of-alzheimer-s-disease
#12
REVIEW
Deepti Mahajan, Marcela Votruba
Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of senile dementia. It impairs the quality of life of a person and their family, posing a serious economic and social threat in developed countries. The fact that the diagnosis can only be definitively made post-mortem, or when the disease is fairly advanced, presents a serious problem if novel therapeutic interventions are to be devised and used early in the course of the disease. There is therefore a pressing need for more sensitive and specific diagnostic tests with which we can detect AD in the preclinical stage...
December 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29203442/n-3-pufa-diet-enrichment-prevents-amyloid-beta-induced-depressive-like-phenotype
#13
M G Morgese, S Schiavone, E Mhillaj, M Bove, P Tucci, L Trabace
Among neuropsychiatric diseases, depression is one of the most prevalent. Many pathologies have been indicated as comorbid with depression and in particular, neurodegenerative disorders such as Alzheimer's diseases (AD). In this regard, several evidences endorse a strong relationship between depression and AD, so much that this mental illness has been proposed either as a risk factor for AD or as a prodromic AD phase. Furthermore, amyloid beta (Aβ) peptide, the main constituent of amyloid plaques commonly considered the principal hallmark of AD brains, has been shown to be increased, in its soluble form, in depressed patients...
December 4, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29201996/a-randomized-exploratory-molecular-imaging-study-targeting-amyloid-%C3%AE-with-a-novel-8-oh-quinoline-in-alzheimer-s-disease-the-pbt2-204-imagine-study
#14
Victor L Villemagne, Christopher C Rowe, Kevin J Barnham, Robert Cherny, Michael Woodward, Svetlana Bozinosvski, Olivier Salvado, Pierrick Bourgeat, Keyla Perez, Christopher Fowler, Alan Rembach, Paul Maruff, Craig Ritchie, Rudy Tanzi, Colin L Masters
Introduction: We are developing a second generation 8-OH quinoline (2-(dimethylamino) methyl-5, 7-dichloro-8-hydroxyquinoline [PBT2, Prana Biotechnology]) for targeting amyloid β (Aβ) in Alzheimer's disease (AD). In an earlier phase IIa, 3 month trial, PBT2 lowered cerebrospinal fluid Aβ by 13% and improved cognition (executive function) in a dose-related fashion in early AD. We, therefore, sought to learn whether PBT2 could alter the Aβ-PET signal in subjects with prodromal or mild AD, in an exploratory randomized study over a 12-month phase in a double-blind and a 12-month open label extension phase trial design...
November 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/29201644/mean-diffusivity-in-cortical-gray-matter-in-alzheimer-s-disease-the-importance-of-partial-volume-correction
#15
Judith Henf, Michel J Grothe, Katharina Brueggen, Stefan Teipel, Martin Dyrba
Mean diffusivity (MD) measured by diffusion tensor imaging can reflect microstructural alterations of the brain's gray matter (GM). Therefore, GM MD may be a sensitive marker of neurodegeneration related to Alzheimer's Disease (AD). However, due to partial volume effects (PVE), differences in MD may be overestimated because of a higher degree of brain atrophy in AD patients and in cases with mild cognitive impairment (MCI). Here, we evaluated GM MD changes in AD and MCI compared with healthy controls, and the effect of partial volume correction (PVC) on diagnostic utility of MD...
2018: NeuroImage: Clinical
https://www.readbyqxmd.com/read/29198280/alzheimer-s-disease-past-present-and-future
#16
Mark W Bondi, Emily C Edmonds, David P Salmon
Although dementia has been described in ancient texts over many centuries (e.g., "Be kind to your father, even if his mind fail him." - Old Testament: Sirach 3:12), our knowledge of its underlying causes is little more than a century old. Alzheimer published his now famous case study only 110 years ago, and our modern understanding of the disease that bears his name, and its neuropsychological consequences, really only began to accelerate in the 1980s. Since then we have witnessed an explosion of basic and translational research into the causes, characterizations, and possible treatments for Alzheimer's disease (AD) and other dementias...
October 2017: Journal of the International Neuropsychological Society: JINS
https://www.readbyqxmd.com/read/29190651/apoe-allele-frequencies-in-suspected-non-amyloid-pathophysiology-snap-and-the-prodromal-stages-of-alzheimer-s-disease
#17
Timothy J Hohman, Logan Dumitrescu, Amy Oksol, Madison Wagener, Katherine A Gifford, Angela L Jefferson
Biomarker definitions for preclinical Alzheimer's disease (AD) have identified individuals with neurodegeneration (ND+) without β-amyloidosis (Aβ-) and labeled them with suspected non-AD pathophysiology (SNAP). We evaluated Apolipoprotein E (APOE) ε2 and ε4 allele frequencies across biomarker definitions-Aβ-/ND- (n = 268), Aβ+/ND- (n = 236), Aβ-/ND+ or SNAP (n = 78), Aβ+/ND+ (n = 204)-hypothesizing that SNAP would have an APOE profile comparable to Aβ-/ND-. Using AD Neuroimaging Initiative data (n = 786, 72±7 years, 48% female), amyloid status (Aβ+ or Aβ-) was defined by cerebrospinal fluid (CSF) Aβ-42 levels, and neurodegeneration status (ND+ or ND-) was defined by hippocampal volume from MRI...
2017: PloS One
https://www.readbyqxmd.com/read/29187334/cognitive-profile-in-prodromal-disease-dementia-with-lewy-bodies
#18
Jennifer Kemp, Nathalie Philippi, Clélie Phillipps, Anne Botzung, Frédéric Blanc
This paper reviews findings on cognition in prodromal dementia with Lewy bodies (DLB). The issue of differential diagnosis between DLB and Alzheimer's disease (AD) on the one hand, and Parkinson's disease (PD) on the other hand, at prodromal stages of the diseases is discussed. The cognitive profile of prodromal DLB is also evaluated in terms of cognitive deficits and « cognitive weaknesses » (low performances although in normal range). Findings suggest that visuo-constructive tests and verbal fluency are particularly relevant to dfferentiate DLB from AD...
December 1, 2017: Gériatrie et Psychologie Neuropsychiatrie du Vieillissement
https://www.readbyqxmd.com/read/29181491/clinical-development-of-aducanumab-an-anti-a%C3%AE-human-monoclonal-antibody-being-investigated-for-the-treatment-of-early-alzheimer-s-disease
#19
S Budd Haeberlein, J O'Gorman, P Chiao, T Bussière, P von Rosenstiel, Y Tian, Y Zhu, C von Hehn, S Gheuens, L Skordos, T Chen, A Sandrock
The amyloid hypothesis has been the dominant framework for Alzheimer's disease (AD) research, including the development of anti-AD therapies. However, none of the phase III clinical trials conducted to date that targeted amyloid β (Aβ) production, aggregation, or clearance demonstrated a statistically significant treatment effect in patients with AD. This includes the approach of using monoclonal antibodies that recognize various Aβ epitopes and display different binding selectivity. While some monoclonal antibodies have failed in phase III trials, several are still in development...
2017: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29167639/disrupted-thalamus-white-matter-anatomy-and-posterior-default-mode-network-effective-connectivity-in-amnestic-mild-cognitive-impairment
#20
Thomas Alderson, Elizabeth Kehoe, Liam Maguire, Dervla Farrell, Brian Lawlor, Rose A Kenny, Declan Lyons, Arun L W Bokde, Damien Coyle
Alzheimer's disease (AD) and its prodromal state amnestic mild cognitive impairment (aMCI) are characterized by widespread abnormalities in inter-areal white matter fiber pathways and parallel disruption of default mode network (DMN) resting state functional and effective connectivity. In healthy subjects, DMN and task positive network interaction are modulated by the thalamus suggesting that abnormal task-based DMN deactivation in aMCI may be a consequence of impaired thalamo-cortical white matter circuitry...
2017: Frontiers in Aging Neuroscience
keyword
keyword
92967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"